Shenweifang-containing serum inhibits transforming growth factor-β1-induced myofibroblast differentiation in normal rat kidney interstitial fibroblast cells

• 作者: LIN Jiaru WANG Li CHEN Bo OU Santao QIN Jianhua FAN Junming
• 来源期刊: 中医杂志（英文版）
• 年，卷（期）: 2022,（1）
• 所属期刊栏目: Research Articles
• 页码范围: 39-48
• 页数: 10页
• 语种: 英文
• DOI: 10.19852/j.cnki.jtcm.2022.01.004

摘要

OBJECTIVE:To investigate the efficacy of Shenweifang(SWF)-containing serum on transforming growth factor(TGF)-β1-induced fibroblast-myofibroblast transition in normal rat kidney interstitial fibroblast cells(NRK-49F).METHODS:Sprague-Dawley rats were gavaged with one of five solutions:(a)saline;(b)saline plus low-dose SWF;(c)saline plus medium-dose SWF;(d)saline plus high-dose SWF;and(e)saline plus valsartan.NRK-49F cells were treated with TGF-β1 and cultured using serum from the gavaged rats.RESULTS:TGF-β1 treatment increased the expression of α-smooth muscle actin,proliferating cell nuclear antigen,collagen I,Smad3,mitogen-activated protein kinase(MAPK)10,and c-Jun N-terminal kinase(JNK)3 and induced abnormalities in cell morphology,cell cycle progression,and cell proliferation.CONCLUSIONS:SWF-or valsartan-containing serum corrected(or partially corrected)TGF-β1-induced abnormal changes in this in vitro system.SWF-containing serum reversed abnormalities in morphology,cell cycle progression,and proliferation in TGF-β1-treated NRK-49F cells,probably by blocking the TGF-β1/Smads and TGF-β1/MAPK/JNK pathways.